- Home
- LEN vs INSM Comparison
LEN vs INSM Comparison
Compare LEN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEN
- INSM
- Stock Information
- Founded
- LEN 1954
- INSM 1988
- Country
- LEN United States
- INSM United States
- Employees
- LEN N/A
- INSM N/A
- Industry
- LEN Homebuilding
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- LEN Consumer Discretionary
- INSM Health Care
- Exchange
- LEN Nasdaq
- INSM Nasdaq
- Market Cap
- LEN 30.9B
- INSM 26.0B
- IPO Year
- LEN N/A
- INSM 2000
- Fundamental
- Price
- LEN $133.80
- INSM $144.75
- Analyst Decision
- LEN Hold
- INSM Strong Buy
- Analyst Count
- LEN 16
- INSM 19
- Target Price
- LEN $128.80
- INSM $146.81
- AVG Volume (30 Days)
- LEN 3.1M
- INSM 2.1M
- Earning Date
- LEN 09-18-2025
- INSM 10-30-2025
- Dividend Yield
- LEN 1.49%
- INSM N/A
- EPS Growth
- LEN N/A
- INSM N/A
- EPS
- LEN 12.16
- INSM N/A
- Revenue
- LEN $35,371,977,000.00
- INSM $398,105,000.00
- Revenue This Year
- LEN $0.05
- INSM $31.95
- Revenue Next Year
- LEN $1.85
- INSM $125.46
- P/E Ratio
- LEN $11.04
- INSM N/A
- Revenue Growth
- LEN N/A
- INSM 21.15
- 52 Week Low
- LEN $98.42
- INSM $60.40
- 52 Week High
- LEN $187.61
- INSM $149.08
- Technical
- Relative Strength Index (RSI)
- LEN 52.80
- INSM 71.03
- Support Level
- LEN $135.57
- INSM $138.73
- Resistance Level
- LEN $140.71
- INSM $148.22
- Average True Range (ATR)
- LEN 3.38
- INSM 3.89
- MACD
- LEN -0.94
- INSM -0.77
- Stochastic Oscillator
- LEN 25.00
- INSM 75.31
About LEN Lennar Corporation
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.